{'fraction_non_alphanumeric': 0.02059202059202059, 'fraction_numerical': 0.0, 'mean_word_length': 5.429752066115703, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Carcinogenicity of Psychotropic Drugs

The use of psychotropic medications has dramatically increased over the past two decades, especially with serotonin reuptake inhibitors and amphetamines. The majority of U.S. prescriptions for psychotropic drugs happen at the primary care level, usually for anxiety and depressive symptoms and their physical correlates. Given the extensive use of these agents, carcinogenic risk should be carefully weighed when prescribing long-term drug therapies. Some psychotropic drugs have some evidence of carcinogenicity based on animal (preclinical) studies. Other agents do not have such evidence. Whether such risk extends into long-term human use is unclear. The animal data are summarized here and available human data also are investigated.